Research & Development


Mochida Pharmaceutical strives to provide medicines that correspond to patients ongoing requirements as quickly as we can.
We maximize foresight and originality in all processes, based on our unique research and development capabilities and diverse technological know-how cultivated over many years.
In order to make our pharmaceutical research even more efficient, we are enhancing development pipelines by introducing candidate drugs for development at an early stage by promoting “open innovation.”


As of May 14, 2018
Code Generic Name Indications Formulation Stage Remarks
LBEC0101 etanercept Rheumatoid arthritis Injection Approved Biosimilar
Licensed-in from LG Chem
AJG555 - Chronic constipation Oral Filed Co-development with EA Pharma
LBAL adalimumab Rheumatoid arthritis Injection Phase Ⅲ Biosimilar
Licensed-in from LG Chem
RGB-10 teriparatide Osteoporosis Injection Phase Ⅲ Biosimilar
Licensed-in from Gedeon Richter

Gout and hyperuricemia Oral Phase Ⅲ Co-development with Fuji yakuhin
MJR-35 dienogest Dysmenorrhea Oral Phase Ⅲ Licensed-in from Jenapharm (a subsidiary of Bayer AG)
MD-0901 mesalazine Ulcerative colitis
Oral Phase Ⅲ <pediatric indication>
Licensed-in from Shire Pharmaceuticals Group
MLD-55 escitalopram Depression
Oral Preparation for Phase Ⅲ <pediatric indication>
Licensed-in from Lundbeck
MD-711 treprostinil Pulmonary arterial hypertension Inhalant Phase Ⅰ Licensed-in from United Therapeutics
[Medical device]
dMD-001 sodium alginate Articular cartilage lesion   Therapeutic exploratory study (Pilot study)